We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Guggenheim lowered the firm’s price target on Regeneron (REGN) to $950 from $1,200 and keeps a Buy rating on the shares. The firm, which is ...
Zacks.com on MSN10d
Regeneron to Report Q4 Earnings: Is a Beat in the Cards?Biotech giant Regeneron Pharmaceuticals, Inc. REGN is slated to report fourth-quarter and full-year 2024 results on Feb. 4, ...
Biotech company Regeneron (NASDAQ:REGN) reported Q4 CY2024 results topping the market’s revenue expectations , with sales up 10.3% year on year to $3.79 billion. Its non-GAAP profit of $12.07 ...
As for revenue, Regeneron reported it at $3.79 billion for the fourth quarter, which was up 10% year over year. The company's full-year haul came in at $14.2 billion, which was an increase of 8%.
Regeneron collaborates with Truveta and leading American health systems to massively extend its DNA-linked healthcare database to further advance scientific innovation and healthcare delivery ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback